| 0.3822 -0.016 (-4.09%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.55 | 1-year : | 0.64 |
| Resists | First : | 0.47 | Second : | 0.55 |
| Pivot price | 0.42 |
|||
| Supports | First : | 0.35 | Second : | 0.29 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.44 |
| MA(100) : | 0.53 |
MA(250) : | 0.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 32.4 |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 1.49 | Low : | 0.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVGN ] has closed above bottom band by 16.7%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.36 - 0.37 | 0.37 - 0.37 |
| Close: | 0.38 - 0.38 | 0.38 - 0.39 |
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Tue, 06 Oct 2026
Holders with 16.94% voting power strike a board deal with Evogene (EVGN). - Stock Titan
Tue, 06 Oct 2026
Holders of about 16.93% sign an Evogene (EVGN) deal that would reshape its board if approved. - Stock Titan
Tue, 06 Oct 2026
Pure Capital nominees could fill four of Evogene's seven board seats. - Stock Titan
Tue, 06 Oct 2026
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors - PR Newswire
Wed, 30 Sep 2026
Director receives 2,500 options with a $0.58 exercise price from Evogene (EVGN). - Stock Titan
Wed, 30 Sep 2026
A director receives 2,500 Evogene (EVGN) stock options with a $0.58 exercise price. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 27.8 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 232 (K) |
| Shares Short P.Month | 249 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.24 |
| Profit Margin | 0 % |
| Operating Margin | -738.7 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -182.8 % |
| Qtrly Rev. Growth | -60.8 % |
| Gross Profit (p.s.) | -0.08 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | -1.6 |
| Price to Sales | 3.63 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|